DK1718737T3 - Cancerøs sygdomsmodificerende antistoffer - Google Patents

Cancerøs sygdomsmodificerende antistoffer

Info

Publication number
DK1718737T3
DK1718737T3 DK05714544.3T DK05714544T DK1718737T3 DK 1718737 T3 DK1718737 T3 DK 1718737T3 DK 05714544 T DK05714544 T DK 05714544T DK 1718737 T3 DK1718737 T3 DK 1718737T3
Authority
DK
Denmark
Prior art keywords
antibodies
cancer
cancerous disease
modifying antibodies
segregating
Prior art date
Application number
DK05714544.3T
Other languages
English (en)
Inventor
David S F Young
Susan E Hahn
Lisa M Cechetto
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1718737T3 publication Critical patent/DK1718737T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK05714544.3T 2004-02-26 2005-02-28 Cancerøs sygdomsmodificerende antistoffer DK1718737T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54866704P 2004-02-26 2004-02-26
PCT/CA2005/000302 WO2005083064A1 (en) 2004-02-26 2005-02-28 Cancerous disease modifying antibodies

Publications (1)

Publication Number Publication Date
DK1718737T3 true DK1718737T3 (da) 2010-08-09

Family

ID=34911008

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05714544.3T DK1718737T3 (da) 2004-02-26 2005-02-28 Cancerøs sygdomsmodificerende antistoffer

Country Status (15)

Country Link
US (1) US7399835B2 (da)
EP (1) EP1718737B1 (da)
JP (1) JP2008504227A (da)
CN (1) CN1934246A (da)
AT (1) ATE469220T1 (da)
AU (1) AU2005217008A1 (da)
CA (1) CA2557093A1 (da)
DE (1) DE602005021459D1 (da)
DK (1) DK1718737T3 (da)
ES (1) ES2345260T3 (da)
NZ (1) NZ549409A (da)
PL (1) PL1718737T3 (da)
PT (1) PT1718737E (da)
SI (1) SI1718737T1 (da)
WO (1) WO2005083064A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7456259B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7494648B2 (en) 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7452979B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) * 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
WO2008058379A1 (en) * 2006-11-13 2008-05-22 Arius Research Inc. Cancerous disease modifying antibodies
EP2126055A4 (en) * 2007-03-26 2011-11-23 Hoffmann La Roche BY HYBRIDOMA CELL LINE AR51A630.3 PRODUCED TUMOR MODIFYING ANTIBODY 010207-01
BRPI0814116A2 (pt) * 2007-07-16 2015-02-03 Hoffmann La Roche Anticorpo monoclonal citotóxico anticâncer
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en) * 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
NZ222509A (en) * 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
EP0539970B1 (en) * 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
IL105008A0 (en) * 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
EP0686260B1 (en) * 1993-02-05 2003-07-09 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
WO1996000084A1 (en) * 1994-06-24 1996-01-04 Torchilin Vladimir P Use of autoantibodies for tumor therapy and prophylaxis
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US20030138425A1 (en) * 2001-09-21 2003-07-24 Mather Jennie Powell Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US6894149B2 (en) 2001-10-11 2005-05-17 Protein Design Labs, Inc. Anti-HLA-DA antibodies and the methods of using thereof
WO2003086456A2 (en) 2002-04-05 2003-10-23 Arius Research, Inc. Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59

Also Published As

Publication number Publication date
CN1934246A (zh) 2007-03-21
DE602005021459D1 (de) 2010-07-08
EP1718737A1 (en) 2006-11-08
ATE469220T1 (de) 2010-06-15
EP1718737B1 (en) 2010-05-26
JP2008504227A (ja) 2008-02-14
PL1718737T3 (pl) 2010-10-29
US7399835B2 (en) 2008-07-15
WO2005083064A1 (en) 2005-09-09
NZ549409A (en) 2009-12-24
CA2557093A1 (en) 2005-09-09
AU2005217008A1 (en) 2005-09-09
SI1718737T1 (sl) 2010-09-30
PT1718737E (pt) 2010-08-09
US20050191305A1 (en) 2005-09-01
EP1718737A4 (en) 2007-03-28
ES2345260T3 (es) 2010-09-20

Similar Documents

Publication Publication Date Title
WO2007095749A8 (en) Cytotoxicity mediation of cells evidencing surface expression of trop-2
DK1718737T3 (da) Cancerøs sygdomsmodificerende antistoffer
CY1106455T1 (el) Τροποποιητικα αντισωματα καρκινικης νοσου
NO20090342L (no) Cancersykdom-modifiserende antistoffer
WO2004065422A3 (en) Cancerous disease modifying antibodies
BRPI0601736A (pt) métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais
NO20066075L (no) Antistofflegemiddelkonjugater og fremgangsmater
MX2009007619A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2005012361A3 (en) Antibodies raised against colon carcinomas
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
MX2009007617A (es) Anticuerpos modificadores de una enfermedad cancerigena.
MX2009007618A (es) Anticuerpos modificadores de una enfermedad cancerigena.
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
MX2009011667A (es) Anticuerpos de modificacion de enfermedad cancerosa.
ATE483028T1 (de) Antikörper, die krebserkrankungen modifizieren
MX2009001292A (es) Anticuerpos modificadores de enfermedad cancerosa.
DK1360208T3 (da) Fremgangsmåde til fremstilling af cytotoksiske anticancer-antistoffer
NO20091459L (no) Cancerose sykdomsmodifiserende antistoffer
WO2008058380A8 (en) Cancerous disease modifying antibodies
MX2009009919A (es) Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma.
AR070279A1 (es) Anticuerpos modificadores de enfermedades cancerosas (cdma)
BRPI0718609A8 (pt) Anticorpos modificadores de doença cancerosa.
AR072750A1 (es) Anticuerpos modificadores de enfermedades cancerosas
AR070280A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab)
AR071847A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas